01
Sep
Research and development (R&D) collaborations present a win-win opportunity for big pharma and their biotech partners. Pharma companies can use collaborations to supplement their R&D pipelines without the large cash outlays necessitated by acquisitions. By spreading available cash across multiple collaborations, they increase their “shots on goal” of finding the next blockbuster drug/therapy.
Similarly, collaborations are attractive to smaller specialty pharma and biotech companies looking to partner certain noncore assets as a source of nondilutive financing or to accelerate life-saving...